09/29/06
- Alchem Laboratories awarded two long term contracts by the National Cancer Institute
01/12/06 - Alchem Laboratories
co-authors chemistry article in cooperation with Esperion Therapeutics, A Division of
Pfizer Global Research & Development
11/04/05 - Alchem Laboratories listed on Drug Development Technology
07/06/05 - Alchem Laboratories to be exhibitor at 9th Annual
Outsourcing of Pharmaceutical Chemistry, Pre-Clinical Development & Contract
Manufacturing Conference
07/06/05 - Alchem Laboratories present at 5th
Retrometabolism Based Drug Design and Targeting Conference
05/16/05 - Chemists of Alchem Laboratories included in publication and
patents by NPS Pharmaceuticals, Inc.
12/31/04 - Alchem Laboratories publishes series of articles on research
conducted in its laboratories
06/29/04 - Emil Pop, President & CEO of Alchem Laboratories,
authors two chapters in book on cannabinoids
06/17/04 - Alchem Laboratories awarded a contract by The Scripps
Research Institute
Press Releases
09/29/06 - Alchem Laboratories awarded two
long term contracts by the National Cancer Institute
Alachua,
Florida, September 29, 2006 - Alchem Laboratories Corporation (www.alchem.com) announced that it has been awarded two
long term (five years with possibility of extension to seven years) research and development contracts
by the National Cancer Institute (NCI) valued at approximately $7,650,000 for five years
and $11,000,000 for seven years. One of
the contracts involves the synthesis of small molecules, and the other one the
manufacturing of bulk chemicals and drugs required for preclinical and clinical studies;
these compounds will be experimented by the NCI in preclinical studies and in clinical
experiments on human subjects for the treatment of cancer "We are pleased to receive
these contracts as they consolidate us as one of the main providers for the Government and
reconfirm the reliability and quality of our work by one of the most prestigious
institutes of the National Institutes of Health. The contracts also impart long-term
stability to our organization in the conditions in which contract research and development
is becoming more and more competitive” said Emil Pop, Ph.D., founder, president and
CEO of Alchem Laboratories, principal investigator of the contract. Alchem Laboratories, a
custom research and manufacturing organization established in 1996 conducts research and
development work since 1998, when it started its operation at its present site in Alachua.
The company which currently employs some 20 staff members, more than half of which are
Ph.D. level chemists, has successfully accomplished numerous research and development
contracts for a variety of pharmaceutical companies from the United States, France, Israel
and Japan. A five-year contract with
the NCI, which has been awarded in 2001 is about to expire. “The work of our
Synthetic Chemistry and Quality Control departments, directors Dr. Ralf Mueller and Dr.
Jing Yang, respectively, and of the Quality Assurance group, director Raymond Malloy M.S.,
has been outstanding. Principal research scientists Drs. Sergiy Denisenko and Vladimir
Rudchenko, group leader Dr. Otto Geoffroy, as well as research scientist Mrs. Terezia
Mendel, had an important contribution to the successful accomplishment of this contract
and the acquiring of the new ones. Dedicated work of other staff members including Judy
Saxon, controller, Charles Alligood, maintenance manager has been remarkable. As a result
of these awards, the company will continue to grow” added Dr. Pop.
01/12/06 - Alchem Laboratories co-authors
chemistry article in cooperation with Esperion Therapeutics, A Division of Pfizer Global
Research & Development
Alachua, Florida, January 12, 2006
– The article entitled “Influence of Various Central Moieties on the Hypolipidemic
Properties of Long Hydrocarbon Chain Diols and Diacids,” coauthored by scientists of Esperion
Therapeutics and Alchem Laboratories, appeared in the first 2006 issue of the Journal of
Medicinal Chemistry (J. Med. Chem. 2006, 49, 334-348). This work is part of a larger effort dealing with
the study of the lipid regulating properties of novel compounds, designed and synthesized
as potential agents in the treatment of metabolic diseases. The results have been
published in several articles.
11/04/05 - Alchem Laboratories listed on
Drug Development Technology
Alachua, Florida, November 4, 2005
– Alchem Laboratories is now listed on Drug Development Technology (http://www.drugdevelopment-technology.com/),
the website for the drug development industry published by SPG Media Limited, a subsidiary of SPG Media Group PLC.
07/06/05 - Alchem Laboratories to be
exhibitor at 9th Annual Outsourcing of Pharmaceutical Chemistry, Pre-Clinical
Development & Contract Manufacturing Conference
Alachua,
Florida, July 6, 2005 – Alchem Laboratories will be a sponsor/exhibitor at the 9th
Annual Outsourcing of Pharmaceutical Chemistry, Pre-Clinical Development & Contract
Manufacturing Conference to be held from July 18-19, 2005, at the Hyatt Regency hotel,
Jersey City, NJ. Alchem Laboratories will be represented at the conference by Emil Pop,
Ph.D., President & CEO, and Jing Yang, Ph.D., Associate Director of Quality Control.
07/06/05 - Alchem Laboratories present at 5th
Retrometabolism Based Drug Design and Targeting Conference
Alachua,
Florida, July 6, 2005 – Alchem Laboratories was a gold-level sponsor of the 5th
Retrometabolism Based Drug Design and Targeting Conference held from May 8-11, 2005, in
Hakone, Japan. Dr. Emil Pop, President & CEO of Alchem Laboratories, a member of the
International Advisory Board, has also served as chair for one of the podium sessions. In
addition, Alchem Laboratories presented a poster in collaboration with Esperion
Therapeutics, a Division of Pfizer Global Research and Development.
05/16/05 - Chemists of Alchem Laboratories
included in publication and patents by NPS Pharmaceuticals, Inc.
Alachua,
Florida, May 16, 2005 – Chemists of Alchem Laboratories were included as authors in a
publication and two patents of NPS Pharmaceuticals, Inc., Salt Lake City, UT. The title of
the publication in Bioorg. Med. Chem. Lett. 2005, 15, 2537-2540 was
“Design, new synthesis, and calcilytic activity of substituted 3H-pyrimidin-4-ones”
and the patents were titled “Methods for Preparing 2,3,5,6-Substituted 3H-Pyrimidin-4-ones”
(WO 2004/092121) and “Pyrimidinone Compounds as Calcilytics” (WO 2004/092120).
12/31/04 - Alchem Laboratories publishes
series of articles on research conducted in its laboratories
Alachua,
Florida, December 2004 – Alchem Laboratories has recently published in collaboration
with Esperion Therapeutics, a Division of Pfizer Global Research & Development, a
series of articles in prestigious journals. The articles are titled “Long Hydrocarbon
Chain Ether Diols and Ether Diacids That Favorably Alter Lipid Disorders in Vivo” (J.
Med. Chem. 2004, 47, 5183-5197), “Long Hydrocarbon Chain Keto Diols
and Diacids that Favorably Alter Lipid Disorders in Vivo” (J. Med. Chem. 2004,
47, 6082-6099), and “Kilogram-Scale Synthesis of bis(6-Hydroxy-5,5-dimethylhexyl)ether
(ESP24232), A Novel Lipid Lowering Agent” (Org. Prep. Proced. Int. 2004,
36, 587-596).
06/29/04 - Emil Pop, President & CEO of
Alchem Laboratories, authors two chapters in book on cannabinoids
Alachua,
Florida, June 29, 2004 - Emil Pop authored two chapters, titled "The Chemical
Constituents of Cannabis Sativa and the Endocannabinoid System" (with V. Di Marzo)
and “Pharmacology and Medicinal Chemistry of THC” in “Cannabinoids”, a
book edited by Vincenzo Di Marzo, recently published by Kluwer Academic/Plenum Publishers.
06/17/04 - Alchem Laboratories awarded a
contract by The Scripps Research Institute
Alachua, Florida, June
17, 2004 - Alchem Laboratories Corporation announced that it has been awarded a contract
by The Scripps Research Institute. The contract work involves the synthesis of novel
compounds with potential therapeutic application. "We are very excited to receive
this contract from such a prestigious institution, and we hope that it represents only the
beginning of a fruitful collaboration," said Emil Pop, Ph.D., founder, president and
chief executive officer of Alchem Laboratories. A custom research and manufacturing
organization established in 1996, Alchem Laboratories supports various stages of the drug
discovery process by conducting research and development work for a number of
pharmaceutical companies and for the National Cancer Institute. Currently Alchem
Laboratories employs over 20 staff members, some half of them being Ph.D. level chemists.
The Scripps Research Institute, one of the largest, private, nonprofit research
organizations in the United States, has recently extended its operations to South Florida
and will build a large research center in Palm Beach County.
11/21/02
- Dr. Emil Pop becomes Fellow of the American Association of Pharmaceutical Scientists
Alachua, Florida,
November 21, 2002 - Dr. Emil Pop, Founder, President and Chief Executive Officer of Alchem
Laboratories Corporation has been conferred the honor of Fellow of the American
Association of Pharmaceutical Scientists (AAPS). AAPS, the most prestigious society for
pharmaceutical scientists that numbers some 12,000 members from 40 countries all over the
world, designated 10 Fellows at its recent annual Conference and Exposition held in
Toronto, Canada on November 10-14. The primary criterion for selection of AAPS Fellows is
professional competence reflected through scholarly and research contributions to
pharmaceutical sciences such as original articles, scientific presentations and/or
patents.
Emil Pop was recognized as a distinguished contributor and acknowledged leader in the
advancement of the pharmaceutical sciences. The last two decades of his career have been
dedicated entirely to pharmaceutical sciences. He has been involved mainly with the
research and development of prodrugs and chemical delivery systems and with the study of
synthetic nonpsychotropic cannabinoids. He considers the study, which contributed to
diversification and a better understanding of this family of compounds with numerous
potential medical applications, to have been quite exciting and rewarding. Dr. Pop is
convinced that based on these compounds, the future will provide novel therapeutics for
treatment of a range of acute and slowly developing neurological disorders including
traumatic brain injury, stroke, pain and multiple sclerosis.
In 1997, Dr. Pop founded Alchem Laboratories Corporation, a continuously expanding custom
research and development organization. The company, located in Alachua and employing some
25 personnel, mainly highly qualified research chemists, has been represented in the AAPS
Exposition.
08/09/02
- Alchem Laboratories to participate at AAPS Meeting November 2002
Alachua, Florida, August
8, 2002 - Alchem Laboratories will
have a booth at the Association of Pharmaceutical Scientists (AAPS) annual meeting at the
Toronto Convention Center, November 10-14, 2002. For additional information contact info@alchem.com.
03/27/02
- Alchem Laboratories opens new administrative offices
Alachua, Florida, March
27, 2002 - Alchem Laboratories completed the expansion of its Alachua facilty with the
addition of approximately 1,600 square feet to be used as administrative offices. The
former office space, approximately 1000 square feet, is being converted to a scale-up
laboratory.
12/02/01 - Alchem Laboratories begins
expansion of its Alachua facility
Alachua, Florida,
December 2, 2001 - Alchem Laboratories Corporation announced that it has begun an
expansion to its Alachua, Florida facility. The addition to the existing building
will add approximately 1,600 square feet to be used as office space. This addition
will allow current office space to be converted to additional laboratory areas.
09/04/01 - Alchem Laboratories awarded a
5-year contract by the National Cancer Institute
Alachua, Florida,
September 4, 2001 - Alchem Laboratories Corporation announced that it has been awarded a 5-year
contract by the National
Cancer Institute valued at approximately $3.5
million. Contract work
involves the synthesis of bulk chemicals and drugs for the treatment of cancer required
for preclinical and clinical studies. "We are pleased to receive this contract as it
represents recognition of the reliability and quality of our work by one of the most
prestigious institutes of the National Institutes of Health," said Emil Pop, Ph.D.,
founder, president and CEO of Alchem Laboratories, Principal Investigator of the contract.
"This contract also imparts long-term stability to our organization" added Ed
Woo, Ph.D., Director of Chemistry, Principal Assistant of the contract. Alchem
Laboratories, a custom research and manufacturing organization established in 1996
conducts research and development work for a variety of pharmaceutical and chemical
companies from the United States, UK, Israel and Japan. Since 1998, when it started its
operation at its present site in Alachua, the company has been growing rapidly, currently
employing over 20 staff members, more than half of them being Ph.D. level chemists. |
